View in EDS

Dual IL-2/IL-21 priming augments the anti-tumor function of CD16V-CAR/TRAIL-engineered NK cells in combination with monoclonal antibodies.

Saved in:
Bibliographic Details
Title: Dual IL-2/IL-21 priming augments the anti-tumor function of CD16V-CAR/TRAIL-engineered NK cells in combination with monoclonal antibodies.
Authors: Hwang I; SL BIGEN, Inc., Yeonsu-gu, Incheon, Republic of Korea; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Yeonsu‑gu, Incheon, Republic of Korea. Electronic address: ijhwang@slbigen.com., Lee J; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Yeonsu‑gu, Incheon, Republic of Korea. Electronic address: jinulee@yonsei.ac.kr., Kim SW; SL BIGEN, Inc., Yeonsu-gu, Incheon, Republic of Korea; College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Yeonsu‑gu, Incheon, Republic of Korea. Electronic address: swkim@slbigen.com., Sung YC; SL BIGEN, Inc., Yeonsu-gu, Incheon, Republic of Korea; Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), Pohang, Gyeongbuk, Republic of Korea. Electronic address: ycsung@postech.ac.kr.
Source: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2025 Aug; Vol. 189, pp. 118289. Date of Electronic Publication: 2025 Jun 24.
Publication Type: Journal Article
Journal Info: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1950-6007 (Electronic) Linking ISSN: 07533322 NLM ISO Abbreviation: Biomed Pharmacother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1950-6007
DOI:10.1016/j.biopha.2025.118289